Guinea vs Panama: Average cost of multi drug-resistant tuberculosis treatment
Guinea
616 constant 2022 US$
in 2024
Panama
572 constant 2022 US$
in 2024
Guinea rank
71st
Panama rank
74th
Average cost of multi drug-resistant tuberculosis treatment over time
- Guinea
- Panama
How they compare
Guinea currently reports 616 constant 2022 US$ against 572 constant 2022 US$ in Panama, a difference of 44 constant 2022 US$.
That makes Guinea's figure about 1.1 times Panama's.
The two have swapped places 3 times across 5 shared years of data; in 2017 it was Panama ahead.
Guinea ranks 71st and Panama ranks 74th of 92 countries.
Across the 2 decades both report, Guinea averaged higher in 1 and Panama in 1.
Head to head by decade
| Decade | Guinea | Panama | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 637.5 constant 2022 US$ | 5,436 constant 2022 US$ | 4,799 constant 2022 US$ | Panama |
| 2020s | 1,582 constant 2022 US$ | 1,288 constant 2022 US$ | 293.67 constant 2022 US$ | Guinea |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Guinea or Panama?
- Guinea, at 616 constant 2022 US$ against 572 constant 2022 US$ in Panama as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Guinea and Panama?
- 44 constant 2022 US$, with Guinea ahead.
- How many years of comparable data are there for Guinea and Panama?
- 5 years are reported by both, from 2017 to 2024.
- How do Guinea and Panama rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Guinea ranks 71st and Panama ranks 74th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.